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Letter to the EditorA novel human mast cell activation
test for peanut allergyFIG 1. Proportion of activated LAD2 cells expressed as a percentage of
CD631 cells sensitized with plasma from children with PA, PS children, or
NA children and stimulated with peanut extract (1000 ng/mL; A) or anti-
IgE (1 mg/mL; B) and in relation to levels of P-sIgE (C).To the Editor:
Peanut allergy (PA) has a significant effect on patients’ lives, and
therefore an accurate diagnosis is extremely important. Peanut-
specific IgE (P-sIgE) is associated with false-positive results and
overdiagnosis.1 Measurement of Ara h 2–specific IgE is more ac-
curate but is associatedwith false-negative results. Thus a consider-
able proportion of patients need to undergo an oral food challenge
(OFC), the current gold standard to diagnose food allergy.2 OFCs
carry the risk of causing allergic reactions, including anaphylaxis.
With the advent of new treatments for PA, use of reliable in vitro
tests rather thanOFCs to identify eligible patients andmonitor clin-
ical response to treatment is desired.
Previously, we showed that the basophil activation test (BAT) is
highly discriminative between children with PA and children with
peanut sensitization but not allergy (PS children) and can reduce
the number of OFCs.3 Because the BAT requires fresh blood and
10% to 15% of individuals have uninterpretable BAT results
caused by nonresponding basophils (ie, basophils that do
not respond to IgE-mediated but only non–IgE-mediated
stimulants),4,5 we investigated whether the ability to elicit
peanut-induced cell activation could be transferred by passive
sensitization of LAD2 mast cells6 with patients’ plasma.
Children being assessed for PA (n5 174), including 73 children
with PA, 60 PS children and 41 nonsensitized nonallergic (NA)
children, underwent clinical assessment, skin prick tests, blood
collection for immunoglobulin measurement (by using Immuno-
CAP; Thermo Fisher Scientific, Waltham, Mass), and OFCs to
peanut, as previously described.3,7 Participants were grouped as
patients with PA, PS patients, or NA subjects. The allergic reaction
severity was classified according to the method of Ewan and
Clark,8 and the threshold dose was determined as the total amount
of peanut protein ingested during the OFC. The study was
approved by the South East London Research Ethics Committee
2.Whole blood BATs andmast cell activation tests (MATs) to pea-
nut were performed, as previously described.3,9
Statistical analyses were performed with SAS 9.4 software
(SAS Institute, Cary, NC) and JMP Pro software, Version 13.2.1.
Depending on data distribution, nonparametric Wilcoxon tests or
normality-based t tests were used, where specified. Optimal cut
points were estimated from receiver operating characteristic ana-
lyses based on logistic regression models. Relationships between
mechanistic outcomes were analyzed by using stratified linear
models; cubic splines were used to allow for more linear curve re-
lationships between variables. When relationships appeared
linear, Pearson correlation coefficients were reported and visual-
ized with simple linear models and 95% CIs.
LAD2 cells expressed FcεRI and CD32 on their surfaces (see
Fig E1 in this article’s Online Repository at www.jacionline.org).
After addition of patients’ plasma, IgE was detected on the cell
surface. Stimulation index (SI) IgE phycoerythrin-Cy7 was
strongly correlated with plasma total IgE levels (Rs 5 0.914, 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).P < .001; see Fig E2, A, in this article’s Online Repository at
www.jacionline.org) and comparable between children with PA
and PS children (P5 .160; see Fig E2, B). LAD2 cells expressed
lysosomal-associated membrane proteins after stimulation with
peanut extract, anti-IgE, or ionomycin (see Fig E3 in this article’s
Online Repository at www.jacionline.org).
Plasma samples from children with PA, PS children, and NA
children (see Table E1 in this article’s Online Repository at www.
jacionline.org) were tested in the MAT. Activation of mast cells
sensitized with plasma from children with PA after stimulation1
TABLE I. Diagnostic performance of the MAT
Diagnostic cutoffs
Parameters
Optimal cutoff 5 17.2%
of CD631 LAD2 cells
Cutoff to achieve 95%
PPV 5 17.2% CD631
LAD2 cells
Cutoff to achieve 95%
NPV 5 0% CD631 LAD2
cells
Optimal cutoff for
severity 5 24.8% CD631
LAD2 cells
Sensitivity (%) 73 (61-82) 73 (61-82) 99 (92-100) 100 (57- 100)
Specificity (%) 98 (92-99) 98 (92-99) 18 (12-28) 87 (80-92)
PPV (%) 96 (87-99) 96 (87-99) 48 (40-56) 24 (11- 45)
NPV (%) 83 (74-89) 83 (74-89) 94 (73-99) 100 (97-100)
Ninety-five percent CIs are indicated between parentheses.
PPV, Positive predictive value; NPV, negative predictive value.
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tized with plasma from PS children (P < .001) or NA children
(P < .001; Fig 1, A), and the response to anti-IgE was similar
(P5 .543; Fig 1, B). Significant differences in mast cell activation
(P < .001) were observed between children with PA and PS chil-
dren, with similar levels of P-sIgE, for instance ranging between
0.35 and 15 KU/L (Fig 1,C, and see Fig E4 in this article’s Online
Repository at www.jacionline.org). The threshold for P-sIgE
levels above which the MAT was reliable was 0.4 KU/L for
P-sIgE and 0.2 KU/L for Ara h 2–specific IgE (see Fig E5 in
this article’s Online Repository at www.jacionline.org). The
false-positive results for P-sIgE and false-negative results for
Ara h 2–specific IgE are also shown in Fig E5. Patients with se-
vere reactions had greater proportions of activated mast cells
compared with patients withmild-to-moderate reactions or nonal-
lergic patients (see Fig E6 in this article’s Online Repository at
www.jacionline.org). The threshold dose at which children with
PA reacted during the OFC was inversely correlated with the pro-
portion of activated mast cells (rs 5 20.466, P 5 .0016). We
analyzed the utility of the MAT to diagnose PA and to identify
allergic patients at risk of severe reactions by using receiver oper-
ating characteristic curve analyses (Table I and see Fig E7 in this
article’s Online Repository at www.jacionline.org).
MAT results were strongly correlated with BAT results to
peanut (Rs 5 0.808, P < .001; see Fig E8 in this article’s Online
Repository at www.jacionline.org). BATs showed greater diag-
nostic accuracy3 compared with MATs, particularly because of
their greater sensitivity; conversely, MATs provided a conclusive
result for subjects with nonresponding basophils. Twelve children
with PA had positive BAT and negative MAT results; these were
patients with relatively low P-sIgE levels (median, 0.72; inter-
quartile range, 0.27-2.79). Patients with nonresponding basophils
all showed good response to anti-IgE and ionomycin and had an
MAT result to peanut consistent with their allergic status.
The data reported here support the use ofMATs to diagnose PA,
namely in cases with equivocal P-sIgE levels, and also validate
the application of the MAT as a biomarker of PA. The MAT
discriminated children with PA from PS children and overcame
the main limitations of the BAT because the MAT did not require
fresh blood cells from the patient, thus allowing deferred testing,
and provided conclusive results for all subjects with nonrespond-
ing basophils (2 of whom had PA).
Both the BATand MAT had very high specificity when used to
diagnose PA. Although the sensitivity of the BAT was superior,
the enhanced specificity is the key added value of cellular tests
compared with conventional serologic tests when diagnosing
food allergy. TheMAT can be used to diagnose PA in a sequential
way when conventional tests fail, similar to what we proposed for
the BAT3 and when it is either not possible to perform the BATor
the patient has nonresponding basophils.Apart from its use for diagnostics, theMAT identified patients at
risk of severe allergic reactions during OFCs. The sensitivity and
negative predictive value of the MAT’s optimal cutoff for severity
was particularly high, with relatively lower specificity and positive
predictive value, indicating that having aMATresult of greater than
the cutoff does not necessarily mean the patient will have a severe
reaction but that these patients would benefit from more intense
educational measures and closer follow-up.
The MAT and the inhibition of MAT results9 can facilitate
further study of the underlyingmechanisms that determine peanut
reactivity versus tolerance. This is because the MAT can be used
to assess the function of allergen-specific IgE antibodies in their
ability to elicit mast cell degranulation and therefore allergic
symptoms, as well as the ability of antibodies of other isotypes
to interfere with this effect, either by inhibiting, as shown previ-
ously for IgG4,
9 or contributing to the activation of mast cells
and basophils after allergen stimulation. However, this needs to
be explored further. Both the BAT and the MAT are useful to
test samples with equivocal P-sIgE levels to confirm PA and relay
the performance of OFCs that would otherwise have positive re-
sults. Because the MAT uses plasma, which can be stored at low
temperatures for long periods of time, it allows testing samples
collected far from the laboratory or in the past.
The MAT is likely applicable to other food allergens. With the
advent of new treatments for food allergy being approved for
marketing, the MAT might prove to be a useful in vitro assay to
monitor treatment response over time and to explore the mecha-
nisms underlying the observed clinical changes during immuno-
modulatory treatments.
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FIG E1. A-D, Expression of FcεRI (Fig E1, A), FcgRI (Fig E1, B), FcgRII (Fig E1, C), and FcgRIII (Fig E1, D) on the
surfaces of LAD2 cells. E, IgE was detectable on the surfaces of LAD2 cells after sensitization. The histogram
in blue represent nonsensitized LAD2 cells, and the histogram in red represents LAD2 cells sensitized with
plasma from a patient with PA. APC, Allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin;
PerCP, peridinin-chlorophyll-protein complex.
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FIG E2. A, Correlation between IgE levels on the surface of LAD2 cells and
total IgE levels in the plasma that the cells were sensitized with (Rs5 0.914,
P < .001). B, Distribution of stimulation index (SI) IgE phycoerythrin-Cy7 in
LAD2 cells sensitized with plasma from children with PA and PS children
was not significantly different (P 5 .160).
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FIG E3. Expression of lysosomal-associated membrane proteins (LAMPs) on the surface of LAD2 cells after
stimulation with IgE-mediated and non–IgE-mediated stimulants. LAMP-1 (CD107a) and LAMP-3 (CD63)
expression increases with degranulation after stimulation with peanut extract (in red), anti-IgE (in orange),
or ionomycin (in blue), whereas LAMP-2 (CD107b) expression increases with degranulation with ionomycin
but not IgE-mediated stimulants. The gray shaded area corresponds to the negative control (ie, unstimu-
lated cells). APC, Allophycocyanin; FITC, fluorescein isothiocyanate; PerCP, peridinin-chlorophyll-protein
complex.
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FIG E4. Activation of LAD2 cells sensitized with plasma samples from
children with PA and PS children containing similar levels of P-sIgE ranging
between 0.35 and 15.0 KU/L (which correspond to the 95% negative
predictive value and 95% positive predictive value determined for P-sIgE,
respectively). PA, Peanut allergic; PS, peanut sensitized tolerant.
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FIG E5. Proportion of activated mast cells sensitized with plasma samples containing varying levels of
P-sIgE and Ara h 2–specific IgE. The lower limit of specific IgE above which the mast cell activation assay is
reliable was estimated for peanut-specific IgE (0.4 KU/L) and for Ara h 2-specific IgE (0.2 KU/L) by observing
the beginning of the inflection point from a cubic spline with a l value of 0.8 (where the reference line
intersects the smoothed regression line). PA, Peanut allergic; PS, peanut sensitized tolerant; NA, nonsensi-
tized nonallergic.
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FIG E6. Mast cell activation to peanut extract (1000 ng/mL) in patients with
no PA (in blue at left), patients with severe allergic reactions to peanut dur-
ing the OFC (in red), and patients with PA who had mild-to-moderate reac-
tions during the OFC (in blue at right).
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FIG E7. Receiver operating characteristic curve for the MAT to diagnose
peanut allergy (A) and to identify patients at risk of severe reactions (B). The
overall area under the receiver operating characteristic curve was 0.874 for
Fig E7, A, and 0.934 for Fig E7, B.
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FIG E8. Correlation between MAT results and BAT results for the same
patients. Rs 5 0.808 and P < .001 for the whole population and when strat-
ified by allergic groups: 0.649, 0.066, and 0.173 for the PA, PS, and NA
groups, respectively.
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TABLE E1. Antibody levels and BAT and MAT results of the study population
Median (IQR) Patients with PA
Peanut-tolerant subjects
P value*
Peanut-sensitized but
tolerant subjects
Non–peanut-sensitized,
nonallergic subjects
Total IgE (KU/L), n 5 157 324 (116.25 to 759) 163 (49.5 to 572) 43.5 (12.25 to 163.75) .0850
Specific IgE (KUA/L)
Peanut, n 5 173 14.05 (2.15 to 133.25) 1.10 (0.33 to 3.36) 0.01 (0.01 to 0.02) <.0001
Ara h 1, n 5 169 0.27 (0.02 to 27.4) 0.07 (0.01 to 0.34) 0.01 (0.01 to 0.01) .0029
Ara h 2, n 5 169 5.05 (0.39 to 54.5) 0.07 (0.04 to 0.17) 0.01 (0.01 to 0.03) <.0001
Ara h 3, n 5 169 0.04 (0.01 to 1.07) 0.05 (0.02 to 0.2) 0.01 (0.01 to 0.01) .7153
Ara h 8, n 5 168 0.04 (0.01 to 0.68) 0.01 (0.01 to 0.20) 0.01 (0.01 to 0.01) .1953
Ara h 9, n 5 169 0.01 (0.01 to 0.07) 0.02 (0.01 to 0.14) 0.01 (0.01 to 0.01) .0385
BAT to peanut (% CD631 basophils at
10-100 ng/mL peanut extract), n 5 157
36.81 (13.06 to 62.81) 0.5 (20.01 to 1.79) 0.2 (20.02 to 0.68) <.0001
MAT (%CD631 LAD2 cells at
1000 ng/mL peanut extract)
Peanut, n 5 153 28.9 (5.23 to 39.55) 1.1 (20.30 to 2.40) 0.4 (20.43 to 1.20) <.0001
Anti-IgE, n 5 153 14.4 (8.975 to 21.53) 17.4 (8.75 to 22) 10.75 (6.8 to 16.73) .5244
Medians and interquartile ranges are indicated. BAT and MAT results were corrected for the negative control.
IQR, Interquartile range.
*P values refer to the comparison between patients with PA and PS patients by using the Mann-Whitney U test.
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